Diagnosis of lung cancer depends on lung histology or sputum shedding cytology. Screening methods for lung cancer mainly include X-ray chest X-ray and sputum cytology, low-dose spiral CT, blood and sputum biomarkers, and exhalation gas monitoring.
As people's awareness of cancer increases and technology advances, as well as private and government support, these are some of the factors that are expected to drive market growth.
In 2018, the global Lung Cancer Diagnostics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Lung Cancer Diagnostics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Lung Cancer Diagnostics development in United States, Europe and China.
The key players covered in this study
AIT Austrian Institute of Technology
Courtagen Life Sciences
Market segment by Type, the product can be split into
Circulating Tumor Cells
Market segment by Application, split into
Market segment by Regions/Countries, this report covers
Central & South America
The study objectives of this report are:
To analyze global Lung Cancer Diagnostics status, future forecast, growth opportunity, key market and key players.
To present the Lung Cancer Diagnostics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Lung Cancer Diagnostics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.